Evidence for the efficacy of an 8% strontium acetate dentifrice for instant and lasting relief of dentin hypersensitivity.
An 8% strontium acetate, 1040 ppm sodium fluoride-based dentifrice has been demonstrated in in vitro and in situ studies to provide deep and acid-resistant tubule occlusion. Clinical efficacy studies have shown instant and lasting dentin hypersensitivity relief from this dentifrice, which has recently been launched by GlaxoSmithKline Consumer Healthcare as Sensodyne Rapid Relief.
Layer
Teresa
T
GlaxoSmithKline Consumer Healthcare, Weybridge, Surrey, UK. teresa.m.layer@gsk.com
Hughes
Nathan
N
D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D003802:Dentifrices / Q000008:administration & dosage / Q000627:therapeutic use*; D003804:Dentin / Q000187:drug effects / Q000648:ultrastructure; D057133:Dentin Desensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003807:Dentin Sensitivity / Q000517:prevention & control*; D006801:Humans; D008422:Materials Testing; D016032:Randomized Controlled Trials as Topic; D012969:Sodium Fluoride / Q000008:administration & dosage / Q000627:therapeutic use; D013324:Strontium / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000085:Acetates; D003802:Dentifrices; D057133:Dentin Desensitizing Agents; C106741:strontium acetate; D012969:Sodium Fluoride; D013324:Strontium